Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…Abstract Number: 2474 • ACR Convergence 2025
Unveiling the clinical spectrum of ACA-positive SSc-ILD: not as benign as expected
Background/Purpose: Anticentromere antibody (ACA)-positive interstitial lung disease (ILD) in systemic sclerosis (SSc) is traditionally considered less aggressive than anti-topoisomerase I (ATA)-positive ILD. However, its clinical…Abstract Number: 1864 • ACR Convergence 2025
Mitochondrial Dysfunction Drives cGAS-STING–Mediated Type I Interferon Production and Fibrosis in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by type I interferon (IFN-I) production and mitochondrial dysfunction. Emerging evidence suggests that activation of the…Abstract Number: 1573 • ACR Convergence 2025
Health-related quality of life over 15 years in systemic sclerosis: impact of sex and survival
Background/Purpose: Patients with systemic sclerosis (SSc) face an uncertain long‑term outlook; understanding how their health‑related quality of life (HRQoL) changes over time can help them…Abstract Number: 1161 • ACR Convergence 2025
Comparative efficacy, safety and tolerability of antifibrotic therapies across systemic autoimmune diseases
Background/Purpose: To evaluate the efficacy, safety, and tolerability of the antifibrotic agents nintedanib and pirfenidone in the treatment of interstitial lung disease (ILD) associated with…Abstract Number: 0961 • ACR Convergence 2025
Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Background/Purpose: Retinoic acid-related orphan receptor-α (RORα) is a nuclear transcription factor implicated in immune regulation, circadian rhythm, and metabolism. However, its role in fibrotic diseases…Abstract Number: 0688 • ACR Convergence 2025
Total lung capacity is predictive of disease severity and survival in systemic sclerosis: a longitudinal analysis in 2347 patients from the French National Cohort Study
Background/Purpose: Total lung capacity (TLC) is seldom assessed in the prediction of systemic sclerosis (SSc) disease severity.Herein, we utilized the French SSc national database to…Abstract Number: 0884 • ACR Convergence 2025
Risk Score for Early Mortality to stratify for Intensive SSc Therapy
Background/Purpose: Systemic sclerosis (SSc) is a rare disease that often leads to severe complications and premature mortality. Recent advancements in the field have led to…Abstract Number: 0032 • ACR Convergence 2025
Protein Language Model-Guided Homology Identifies Microbial Enzymes Linked to Fibrosis-Prone IgG4-RD and Crohn’s Disease
Background/Purpose: Uncharacterized microbial enzymes in metagenomics are difficult to annotate, especially in fibrosis-prone conditions like IgG4-related disease (IgG4-RD) and Crohn’s disease (CD), where microbial carbohydrate…Abstract Number: 2498 • ACR Convergence 2025
Effect of autologous myeloablative hematopoietic stem cell transplantation on skin and peripheral blood mononuclear cells in systemic sclerosis patients with interstitial lung disease
Background/Purpose: Systemic sclerosis (SSc) is characterized by skin fibrosis, dysregulated immune response, and vascular system dysfunction. Interstitial lung disease (ILD) is one of the leading…Abstract Number: 2473 • ACR Convergence 2025
Nailfold Capillaroscopy Improves Cardiovascular Risk Stratification in Systemic Sclerosis: An Adjustment to the SCORE2 Algorithm
Background/Purpose: Systemic sclerosis (SSc) is associated with both micro- and macrovascular damage, increasing cardiovascular (CV) risk. The SCORE2 algorithm estimates CV event risk in the…Abstract Number: 1863 • ACR Convergence 2025
Bag3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis
Background/Purpose: BAG3 (Bcl2-associated athanogene 3) regulates cellular pathways including apoptosis and autophagy, and induces fibroblast-to-myofibroblast transformation. In systemic sclerosis (SSc), myofibroblasts drive fibrosis of skin…Abstract Number: 1571 • ACR Convergence 2025
Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
Background/Purpose: The skin from patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS) already exhibits fibrotic alterations such as collagen deposition and perivascular infiltration (1),…Abstract Number: 1079 • ACR Convergence 2025
Sociodemographic, Clinical, and Community-Level Deprivation Factors are Associated with Health-Related Quality of Life in Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease with heterogeneous manifestations and significant impairment in health-related quality of life (HRQoL). SSc outcomes are shaped…Abstract Number: 0959 • ACR Convergence 2025
Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
Background/Purpose: Clinically useful biomarkers for systemic sclerosis (SSc) are needed. While obtaining samples from affected organs like the skin and lungs is invasive and cannot…
- 1
- 2
- 3
- …
- 56
- Next Page »